Oramed Pharmaceuticals 将来の成長

Future 基準チェック /26

Oramed Pharmaceuticalsの収益は年間163%で減少すると予測されていますが、年間収益は年間250.9%で増加すると予想されています。EPS は年間139.3%で減少すると予想されています。

主要情報

-163.0%

収益成長率

-139.3%

EPS成長率

Pharmaceuticals 収益成長	21.6%
収益成長率	250.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	25 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:OJU1 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	2	-10	N/A	N/A	1
12/31/2024	N/A	10	N/A	N/A	2
9/30/2024	N/A	4	-8	-8	N/A
6/30/2024	N/A	21	-2	-2	N/A
3/31/2024	1	10	-6	-6	N/A
12/31/2023	1	6	-11	-10	N/A
9/30/2023	2	-16	-17	-17	N/A
6/30/2023	3	-20	-19	-18	N/A
3/31/2023	3	-30	-25	-24	N/A
12/31/2022	3	-37	-28	-28	N/A
9/30/2022	3	-46	-39	-39	N/A
6/30/2022	3	-46	-43	-43	N/A
3/31/2022	3	-40	-39	-39	N/A
12/31/2021	3	-35	-33	-33	N/A
11/30/2021	3	-25	-22	-22	N/A
8/31/2021	3	-22	-22	-21	N/A
5/31/2021	3	-18	-18	-17	N/A
2/28/2021	3	-15	-16	-15	N/A
12/31/2020	3	-22	-26	-25	N/A
11/30/2020	3	-15	-16	-16	N/A
8/31/2020	3	-12	-13	-12	N/A
5/31/2020	3	-11	-13	-13	N/A
2/29/2020	3	-13	-14	-14	N/A
11/30/2019	3	-13	-12	-12	N/A
8/31/2019	3	-14	-13	-13	N/A
5/31/2019	3	-15	-14	-14	N/A
2/28/2019	3	-15	-14	-14	N/A
11/30/2018	3	-14	-16	-16	N/A
8/31/2018	2	-13	N/A	-15	N/A
5/31/2018	2	-12	N/A	-12	N/A
2/28/2018	2	-10	N/A	-11	N/A
11/30/2017	2	-10	N/A	-10	N/A
8/31/2017	2	-10	N/A	-6	N/A
5/31/2017	2	-13	N/A	3	N/A
2/28/2017	2	-13	N/A	3	N/A
11/30/2016	1	-11	N/A	8	N/A
8/31/2016	1	-11	N/A	5	N/A
5/31/2016	0	-8	N/A	-3	N/A
2/29/2016	0	-8	N/A	-2	N/A
11/30/2015	N/A	-8	N/A	-6	N/A
8/31/2015	N/A	-7	N/A	-5	N/A
5/31/2015	N/A	-7	N/A	-5	N/A
2/28/2015	N/A	-7	N/A	-5	N/A
11/30/2014	N/A	-6	N/A	-5	N/A
8/31/2014	N/A	-6	N/A	-4	N/A
5/31/2014	N/A	-5	N/A	-4	N/A
2/28/2014	N/A	-4	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OJU1の収益は今後 3 年間で減少すると予測されています (年間-163% )。

収益対市場: OJU1の収益は今後 3 年間で減少すると予測されています (年間-163% )。

高成長収益: OJU1の収益は今後 3 年間で減少すると予測されています。

収益対市場: OJU1の収益 ( 250.9% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: OJU1の収益 ( 250.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OJU1の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Oramed Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Earnings quality

Investor sentiment deteriorates as stock falls 15%

New minor risk - Market cap size

Investor sentiment improves as stock rises 22%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New major risk - Share price stability

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)

President recently bought €188k worth of stock

Independent Director recently bought €132k worth of stock

Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)

Independent Chairman of the Board recently sold €85k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Independent Chairman of the Board recently sold €376k worth of stock

Independent Director Xiaoming Gao has left the company

Oramed Pharmaceuticals Inc. Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals Inc. Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)

CFO, Treasurer & Secretary Avraham Gabay has left the company

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)

Oramed Pharmaceuticals Inc. Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

New 90-day high: €9.23

New 90-day high: €5.31

Oramed Pharmaceuticals Inc. Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Revenue beats expectations

Revenue beats expectations

First quarter 2021 earnings released: US$0.23 loss per share

Oramed Pharmaceuticals Inc. Reports Positive First in Human Data from Oral Leptin Study

Oramed Pharmaceuticals Inc. Initiates Phase 2 NASH Trial of Oral Insulin

New 90-day high: €3.34

Revenue misses expectations

Oramed Pharmaceuticals Inc Initiates Phase 3 Trial of Oral Insulin

Full year 2020 earnings released: US$0.56 loss per share

New 90-day low: €2.13

New 90-day low: €2.32

New 90-day low - €2.90

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想